Log In
Wednesday 21st March 2018

Clinical trials of drug for rheumatoid arthritis stopped

20th May 2010

Clinical trials involving a drug called ocrelizumab in patients with rheumatoid arthritis have been halted after scientists analysed data and found that other available treatments provided more favourable results.

The drug had been the focus of four phase-III trials as part of a development programme by Roche and Biogen. Arthritis Research UK has expressed its disappointment that the ocrelizumab clinical research programme has had to be stopped but said it acknowledged that the potential risk of serious, possibly fatal, infections justified this action.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2018